Section 05: Business Model & Economics
Unit Economics Dashboard
1. Revenue Model Overview
Primary: Freemium SaaS Subscription (55% of revenue)
Monthly/annual plans for patients/caregivers. Predictable MRR aligns with high-touch health needs; freemium drives viral adoption in patient communities. Fits market as users seek ongoing trial monitoring amid chronic conditions.
Secondary: B2B Lead Fees (35% of revenue)
$100 per qualified patient lead to pharma/CROs. Captures recruitment value ($2B market pain); ethical opt-in model ensures compliance and trust.
Tertiary: Enterprise Licensing (10% of revenue)
Custom white-label for hospitals/pharma ($5K-20K/mo). High-margin, sticky via integrations; scales post-Year 1 validation.
Evolution: Year 1: Freemium focus (80% rev). Year 2-3: Ramp B2B (to 40%). Maturity: 50/40/10 mix for diversification.
2. Pricing Strategy & Tier Structure
Pricing Psychology: Anchor Pro as "best value" (2.5x features for 2.5x price). $9.99 entry beats competitors (Antidote ~$15/mo inferred); annual discount boosts cash flow. Good-Better-Best drives 20% upsell.
Market Benchmarks:
| Competitor | Entry | Mid | Enterprise | Your Position |
|---|---|---|---|---|
| Antidote | $15/mo | N/A | Custom | 33% cheaper entry |
| TrialSpark (B2B) | N/A | $10K/mo | Custom | Patient-direct edge |
| ClinicalTrials.gov | Free | Free | N/A | Premium UX wins |
| Clinical Trial Navigator | $9.99 | $24.99 | Custom | Value leader |
Justification: Delivers $10K+ ROI via trial access (e.g., 1% enrollment chance at $1M+ therapies). Elasticity high post-validation; competitors lack AI personalization. Add-ons: $5/mo extra conditions.
3. Customer Acquisition Economics
| Channel | Monthly Spend | Conversions | CAC | Notes |
|---|---|---|---|---|
| Content/SEO (patient blogs) | $3,000 | 80 | $38 | Condition-specific guides |
| Paid Social (FB patient groups) | $4,000 | 50 | $80 | Targeted chronic illness ads |
| Google Ads (trial searches) | $3,500 | 40 | $88 | High-intent keywords |
| Patient Community Partnerships | $1,500 | 40 | $38 | Rare disease org affiliates |
| Total | $12,000 | 210 | $58 | Blended
CAC Plan: M1-3: $85 (ramp). M4-6: $70. Y2+: $45 (50% organic from communities/SEO). Viral K=0.8 (patient shares). Effective CAC w/organic: $42.
4. Lifetime Value (LTV) Analysis
ARPU: $18/mo (60% Premium@10, 25% Pro@25, 15% B2B equiv). Churn: 5%/mo (health loyalty; cohorts: M3 88%, M12 65%). Gross Margin: 78%.
LTV = $18 × 78% × (1/0.05) = $547. LTV:CAC 9.4:1 ✅. Sensitivity: 2x CAC → 4.7:1 (still viable); 50% churn rise → LTV $274 (5:1).
Improvements: Upsells (ARPU +20%), onboarding (churn -1%), B2B ramp.
5. Cost Structure & Margins
Fixed (Monthly):
| Category | Amount | Notes |
|---|---|---|
| Salaries (3 FTE) | $15,000 | Incl. clinical advisor |
| Tools/Hosting | $1,200 | AWS, LLM APIs |
| Marketing | $2,000 | Baseline |
| Legal/Compliance | $1,500 | HIPAA ongoing |
| Total Fixed | $19,700 | $236K/yr |
Variable (Per User/Mo): $4 (AI $2.50, hosting $0.80, support $0.70). Gross Margin: ($18-$4)/$18 = 78%.
Op Margin @Scale: 1K users: 62%; 5K: 75%.
6. Break-Even Analysis
Break-Even = $19,700 / ($18 - $4) = 1,071 customers.
| Scenario | New Cust/Mo | Break-Even Month |
|---|---|---|
| Conservative | 30 | 12 |
| Base | 50 | 7 |
| Optimistic | 80 | 5 |
| Month | Customers | MRR | Costs | P/L | Cumulative |
|---|---|---|---|---|---|
| 3 | 200 | $3,600 | $24K | -$20K | -$60K |
| 7 | 1,100 | $19,800 | $24K | -$4K | -$120K |
| 12 | 2,000 | $36K | $28K | +$8K | +$20K |
7. Revenue Projections (3-Year)
| Metric | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Paying Customers | 1,200 | 4,000 | 10,000 |
| Free Tier | 5,000 | 15,000 | 30,000 |
| Conversion | 19% | 21% | 25% |
| MRR (EoY) | $21,600 | $72,000 | $180,000 |
| ARR | $300K | $864K | $2.16M |
| Growth | - | 188% | 150% |
| Total Costs | $350K | $650K | $1M |
| CAC | $58 | $48 | $40 |
| LTV | $547 | $624 | $720 |
| Net Profit | -$50K | $214K | $1.16M |
| Net Margin | -17% | 25% | 54% |
Assumptions: 50/mo →150/mo acquisition; ARPU $18→$21→$24; churn stable. Sensitivity: Worst (50% slow): $1.1M Y3 ARR.
9. Funding Strategy & Use of Funds
Bootstrap: $150K savings for 12-mo runway; moderate growth.
Raise (Recommended): $500K seed (10-15% dilution); aggressive B2B push.
| Category | Amount | % | Purpose |
|---|---|---|---|
| Engineering | $250K | 50% | 2 FTE + clinical |
| Marketing | $100K | 20% | Patient communities |
| Compliance/Legal | $75K | 15% | HIPAA/SOC2 |
| Ops/Salaries | $50K | 10% | Runway buffer |
| Total | $500K | 100% | 18-mo runway |
Seed→A: $1M ARR, 15% MoM growth, <5% churn.
10. Regulatory, Compliance & Legal
Entity: Delaware C-Corp (VC-friendly, IP protection).
- HIPAA/SOC2: Essential ($50K Y1 setup + $20K/yr). FHIR encrypted, min data retention.
- Privacy: GDPR/CCPA; disclaimers vs. medical advice ($5K policy).
- IP: Trademark app ($1K); trade secrets on AI matching.
- Insurance: Cyber ($3K/yr), D&O ($2K).
- Total Compliance: $80K Y1, $30K/yr.
11. Business Model Risks & Mitigations
| Risk | Severity | Likelihood | Impact | Mitigation |
|---|---|---|---|---|
| AI Cost Spike (LLM) | 🔴 High | Medium | Margin -20% | Multi-LLM (OpenAI+Anthropic), caching parsed criteria, cap free usage. Monitor quarterly; negotiate vol discounts Y2. |
| High Churn Post-Enrollment | 🟡 Med | High | LTV -40% | Alumni features (post-trial tracking), re-engagement emails. Track cohorts; CS for high-value. |
| Regulatory (HIPAA Breach) | 🔴 High | Low | $1M+ fines | SOC2 audit Y1, annual pen-tests, DPA for B2B. Insurance coverage; user consent flows. |
| Slow B2B Adoption | 🟡 Med | Medium | Rev -30% Y1 | Pilot 3 pharma partners Q1; ethical lead opt-in demos. Track lead quality KPIs. |
| CAC Inflation (Ad Competition) | 🟡 Med | Medium | Scale impeded | 60% organic target via communities/SEO. Viral loops in app. |
| Lead Quality Disputes (B2B) | 🟢 Low | Low | Rev refunds | Strict qual criteria, trial-out guarantees. Feedback loop with partners. |
12. Alternative Business Models
Alt #1: Pure B2B Lead Gen (10% trial fee)
Pros: High rev/trial. Cons: Patient distrust, regulatory scrutiny. Rejected: Alienates core users; freemium builds trust/scale first.
Alt #2: One-Time Matching Fee ($49/trial)
Pros: Upfront cash. Cons: No recurring, misses monitoring value. Rejected: Chronic needs demand subscription; LTV 70% lower.
Why Current Best: Freemium acquires volume cheaply in fragmented patient market; B2B diversifies w/o cannibalization. Benchmarks (Antidote hybrid) validate; 9:1 LTV:CAC proves scalability vs. transaction volatility.